Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Intermediate saphenous vein graft (SVG) lesions are common, have high rates of progression to
severe lesions or occlusion, and are associated with high incidence of adverse clinical
outcomes.
The ALPINE-SVG trial is a randomized-controlled trial of extended-release niacin vs. placebo
in patients with intermediate saphenous vein graft lesions. The main hypothesis of the study
is that compared to placebo, niacin administration will result in reduction in percent
atheroma volume at 12-month follow-up angiography.
Phase:
Phase 2
Details
Lead Sponsor:
North Texas Veterans Healthcare System
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)